Freedom Leaf recently announced a historic partnership with one of the country’s oldest, largest and most recognizable non-profit pro-cannabis advocacy groups, The National Organization for the Reform of Marijuana Laws (NORML). Following the execution of a brand management agreement, the NORML board of directors named Freedom Leaf as its manager of business partnerships, new events and merchandising. This collaboration is expected to boost the group’s brand awareness and revenue in the months to come as it continues to focus on its ultimate goal of ending cannabis prohibition across the nation.

“Freedom Leaf, Inc. is proud to have been chosen to be the brand ambassador of NORML,” Cliff Perry, chief executive officer of Freedom Leaf, stated in a news release. “Our vision is to promote and support donations, membership, the NORML Legal Committee (NLC), business networking events, musical festivals, NORML merchandise and educational seminar components.”

NORML was originally founded over 45 years ago and currently boasts more than 140 chapters and a national headquarters in Washington, D.C. The group’s volunteers and advocates have been credited as a driving force behind the evolving legal landscape surrounding cannabis – including the introduction of bills to legalize medical cannabis, hemp and recreational marijuana, as well as those to decriminalize possession.

The Freedom Leaf team is intimately familiar with NORML’s mission. The company’s co-founder, Richard Cowan, served as national director of NORML from 1992 to 1995, and he contributed approximately $200,000 in cash contributions last year. In a news release, Cowan described the frustrations associated with raising funds and vetting prospective partnerships, which are both essential to the viability of NORML and a distraction from the group’s overarching goals. Moving forward, Freedom Leaf will manage many of the business aspects of NORML, allowing the group to remain focused on its efforts to end cannabis prohibition.

As part of the agreement, Freedom Leaf is now authorized to solicit companies to join the NORML Business Network, assist in vetting offers from companies interested in licensing the NORML brand and undertake other commercial activities that bring revenue to NORML in exchange for earned agency revenue.

Over the past half-century, NORML’s efforts have had a major impact on shifting popular opinion regarding cannabis prohibition. In 1969, only 12 percent of Americans favored marijuana legalization, according to a study by Pew Research. However, in a March 2015 poll, a majority of 53 percent stated that the drug should be made legal. To date, marijuana has been legalized or decriminalized in 27 states and the District of Columbia.

For more information, visit http://freedomleaf.com

Let us hear your thoughts: Freedom Leaf Inc. Message Board

For many parents in LA, whether they are A-list celebrities like Jennifer Garner and Ben Affleck, or Jessica Alba and her beau, or some of the nearly four million other inhabitants of this sprawling metropolis, there is only one place to take the kids for a birthday party: Giggles N’ Hugs (OTCQB: GIGL). Never before in the history of the casual dining restaurant business has there been a venue such as this, which combines top shelf organic food and elegant dining for adults, with a decided emphasis on entertaining children and giving them someplace to enjoy healthy play while their parents relax. With the roughly 6,000 square foot family restaurant floor space divided between the upscale dining section and a 2,000 square foot plus Gymboree-style play area for the kids – full of fun interactive/tactile toys, as well as climbers, ball pits and thematic elements such as magic castles, dragons and pirate ships – Giggles N’ Hugs has quickly become the go-to place for birthday parties.

With three locations throughout the LA area to choose from, located in upscale shopping centers like Century City’s Westfield Mall, the Glendale Galleria and the Westfield Topanga Shopping Center, parents never have too far to go to enjoy the benefits of being a GIGL customer, with service options like being able to drop their kids off to play at Giggles N’ Hugs while they go shopping. Giggles N’ Hugs is staffed by friendly, trained personnel who keep an eye on the kids and keep them busy, helping to coordinate periodic events that take place throughout the day, like face painting, sing along karaoke, or arts and crafts, and even full-on shows hosted by local child entertainers featuring music, puppetry, and other fun activities.

With a two hour party for 15 guests costing only $350, featuring numerous amenities such as fully orchestrated themes, organic food, beverages, fresh desserts, custom-crafted confections and fun activities that are not available at competing locations such as Chuck E. Cheese, Giggles N’ Hugs has rapidly made a name for itself as the highest value for parent’s party dollar. With an unrivaled variety of themes available for boys and girls to choose from, ranging from superheroes or princesses, to pirates or mermaids and many, many more, birthday parties thrown by Giggles N’ Hugs offer not only nonstop excitement and exercise, but lovingly crafted foods and desserts, as well as gift bags stuffed with themed prizes.

And now the fun is coming to customers via the company’s superb party creation teams, with fully catered, themed in-home parties available, featuring all the amenities parents and kids have come to know and love, minus the awesome Giggles N’ Hugs locale. What these in-home designer parties may lack in access to the wonderful playspaces available at Giggles N’ Hugs locations, they more than make up for in terms of convenience, and the ability to host blowout extravaganzas for lucky little boys and girls who get to be the star of the party, thrown right in their own home where they are most at ease. The company’s award-winning, professional staff takes care of every detail from setup to cleanup, allowing parents to focus on making the day a special one that their child will never forget. And the GIGL party planners stand at the ready to help parents craft the ultimate customized birthday party for their kids, bringing a highly tailored experience to consumers which has resonated far and wide, channeling new customers organically via word of mouth alone.

Little wonder then that Giggles N’ Hugs has been rated the number one kids party place in LA by popular children’s network Nickelodeon. And this kind of coverage is just the tip of the iceberg for GIGL, with numerous write-ups in leading celebrity-focused publications, as well as the mainstream media. Expansion plans to take this winning model nationwide and even into choice global markets have already been executed, with GIGL coordinating the rollout in conjunction with close ally Westfield, which owns and operates a huge number of malls and shopping centers both at home and abroad. Many analysts are convinced that we are witnessing the birth of an industry-defining franchise here and investors should take note of the opportunity to get in before the operation goes supernova, landing new locations across the country on the strength of the Giggles N’ Hugs business model, which presents mall owners with a highly synergistic tenant that can help attract customers to their venues other retail tenants.

Get a closer look at this wining business model by visiting www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Oakridge Global Energy Solutions is an integrated energy storage solutions company that uses state-of-the-art technology in the design, development and manufacture of high-quality cells, batteries and energy storage systems. The company is committed to ushering in a brand new era in battery manufacturing, and a quick look at its core values highlights the commitments that help Oakridge differentiate itself from the competition in the stored energy marketplace.

An unrelenting dedication to corporate pride and commercial success forms the foundation of the Oakridge business model, and a commitment to innovation has allowed the company to develop a diverse, ‘Made in the U.S.A.’ product line that addresses four high-demand target markets – including motive applications, stationary living space power, remote control and portable devices, and starter motor batteries. In October, Oakridge expanded on this formula by announcing the production release of its Pro Series product line of heavy duty battery systems for task-oriented vehicles.

“This is a very exciting product line and we are really pleased with the way that it underscores our mission statement of on-shoring jobs and manufacturing back to the U.S.A. by providing the market with another Made in the U.S.A. product instead of having to rely on imported products,” Steve Barber, executive chairman and chief executive officer of Oakridge, stated in a news release.

The company’s focus on bringing manufacturing jobs back to the U.S. has caught the attention of local lawmakers and entrepreneurs. Last month, Oakridge was recognized by Florida Governor Rick Scott following the launch of its new corporate headquarters and manufacturing center in Palm Bay. The expansion, which is part of Oakridge’s existing and ongoing $270 million investment in its lithium-ion battery development and manufacturing facilities in Brevard County, Florida, is expected to create approximately 1,000 new jobs in the community.

According to a study by Research and Markets, the global lithium-ion battery market is expected to grow at a CAGR of 14.4 percent over the next four years, reaching $33.1 billion by 2019. While much of this growth is expected to occur in the automotive sector, global sales of lithium-ion powered energy storage systems are also expected to increase from less than $2 billion in 2015 to roughly $6 billion by 2020.

By providing high-quality products that address a number of viable markets, Oakridge is in a strong position to capitalize on this market growth in the years to come. Look for the company to build upon the early success of its current product line as it continues to target key niche market segments with its lithium-ion battery products in the future.

For more information, visit www.oakg.net

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

When it comes to fun and excitement, Latitude 360 (QTCQB: LATX) shareholders will not find the company sitting on its laurels. As if a grille and bar, luxury bowling lanes, a dine-in movie theater with HD sports theater- and game room were not enough to tantalize one’s senses, the company has recently added to its multi-dimensional experience the skyrocketing attraction of daily fantasy sports.

360 Fantasy Live is anticipated to boost Latitude 360’s overall entertainment concept and enhance the experience of watching the games – while also driving revenue through high guests average check from longer visits watching games and revenue from 360 Fantasy Live contests.

In addition to great food, spirits and 360 Fantasy Live, Latitude 360’s Jacksonville, Pittsburgh and Indianapolis locations also offer dine-in, Vegas-style live performance theaters, HD sports theaters, bars, dance floors and stages for DJs, state-of-the-art video arcade and the area’s best private events. Fully involved from start to finish with its endeavor, the company plans, develops, builds and operates its venues to deliver its unique “360 Experience.”

For more information on the company visit www.latitude360.com

Let us hear your thoughts: Latitude 360, Inc. Message Board

Early detection of cancer is the key to using the medicines available today to battle cancer and give the patient the best chance of beating this horrible disease and getting back to a normal life. Avant Diagnostics (AVDX) has undertaken this heroic challenge with its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test.

OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

Each year, cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR).

Cancer costs $895 billion annually. Comparatively, heart disease costs $753 billion. Nothing else comes close, with traffic accidents and diabetes each costing about $204 billion. More than half a million Americans die of cancer, the second-leading cause of death in the U.S., every year.

Cancer is like any disease, ailment, or problem in that the earlier you correctly identify and get to work on fixing it, the better your chances are… Let’s just use Peyton Manning as a good example of what to do. When he throws an interception, he immediately goes to the sideline, talks to coaches, studies stills of defensive alignments and identifies what he could have done better to throw a touchdown instead of the interception.

Using a product like OvaDx would be the best way to identify the exact nature of the problem, so experts and doctors can recommend the best treatments to ensure your survival. Cancer does not discriminate, as you can see from the above study, and takes very few prisoners, especially when you sit back and do nothing. Companies developing state of the art technology like AVDX give patients the best chance at beating this horrible disease and living a long and happy life.

In conclusion, put AVDX on your radar, especially considering recent FDA developments. It would be well worth your time to educate yourself a little more on early cancer detection and participate in the battle affecting everyone in the world today.

For more information, visit www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

Crowdfunding is a rapidly growing industry. In 2010, the global online crowdfunding market was valued at roughly $880 million, led by a relatively small audience of early adopters. Just four years later, crowdfunding platforms accounted for approximately $16 billion in total investments, and that figure is expected to exceed $34 billion by the end of this year. To better illustrate the scale of this growth, consider the venture capitalism industry, which has traditionally served as the ‘go-to’ source of capital for startups and other pre-revenue companies.

Currently, the VC industry invests an average of $30 billion each year, led by global firms such as Fortress Investment Group (NYSE: FIG), American Capital (NASDAQ: ACAS) and Apollo Investment Corp. (NASDAQ: AINV), but industry growth is expected to remain relatively flat in the coming years. In other words, the crowdfunding industry is on track to account for more funding than the VC industry as early as next year.

One of the primary benefits of crowdfunding is its versatility. Companies such as Kickstarter and GoFundMe have captured market share through the implementation of a simple rewards-based system. Using this model, investors gain access to varying levels of rewards corresponding to the amount they pledge to the business or project. However, the Jumpstart Our Business Startups (JOBS) Act – which was signed into law by President Obama in April 2012 – set the stage for a crowdfunding model based on a more traditional investment incentive: equity.

Equity crowdfunding is just one of the many investment models offered by Symbid Corporation (OTCQB: SBID) through its proprietary investment platform, The Funding Network™. Founded in 2011, Symbid was one of the first companies to identify the rising need for data-driven SME finance and invest in the development of advanced investing, monitoring and data tools. Leveraging this early mover advantage, Symbid launched The Funding Network in March 2015 in order to give entrepreneurs direct access to all forms of financing while offering investors complete transparency on the potential risks and returns of their portfolios.

In the third quarter of 2015, Symbid demonstrated the marketability of its platform by recording a 30 percent year-over-year increase in total revenues. In its first six months of operation, The Funding Network has seen a total transactional volume of nearly $400 million. In July, Symbid successfully added roughly 2,000 new investors to its crowdfunding community and recorded its first success fees stemming from the introduction of its innovative loan crowdfunding product, effectively paving the way for additional growth in the months to come.

“The diversified product portfolio of The Funding Network has delivered promising results in the first six months since its launch in March and is creating real value for investors and entrepreneurs,” Korstiaan Zandvliet, co-founder and chief executive officer of Symbid, stated in a news release. “Clearly there is huge potential to further commercialize our transaction volume. The consistent growth in revenue we’ve been seeing in 2015 gives us the foundation to do just that while we continue to innovate at the forefront of online funding.”

For more information, visit www.symbid.com

Being a top dog in the pet industry means more scalability to reach a wider customer base. That’s why OurPet’s Company (OTCQX: OPCO) gives two brand options to its niche customers. The OurPets brand focuses on specialty customers while the Pet Zone Brand centers on food/drug/mass-market channels. Each has its own website where pet owners can get the latest products in safety, health, waste management, and fun.

OurPet’s designs, produces, and markets a variety of innovative, high quality accessory and consumable pet products in the United States and overseas. It began with the Big Dog Feeder product that improves posture and comfort for canines. Most of their award-winning products are patented and boast being the only ones of their kind on the market. Cat owners can get their own consumable Kitty Cat Grass to grow at home or the EZ Scoop Litter Box with Odor Control Spray. Felines can also frolic with the Hide and Go Squeak Interactive Toy. Dogs can have the Buster Food Cube and the WonderBowl for their eating needs. The company’s products aim at bringing out a pet’s natural instincts for a healthier lifestyle.

In 2006, OurPet’s purchased all of the assets of its chief competitor, Pet Zone. The company now has a platform for its own products while integrating those of Pet Zone in another. Pet Zone products and accessories aim at improving the health, vitality, and safety of pets. Its goal is to offer high-end products at affordable rates. Feline friends can purchase the Mini Food-N-Fountain Deluxe or the Purr-Ivacy Place Pop-Up Litter Box Canopy along with many scratchers and toys. Dog owners can buy the Cozy Cottage Dog House, treat dispensers, and other food bowl accessories.

The pet industry has grown from $17 billion in 1994 to $74.23 billion in 2014. That number is expected to increase to $77.03 billion this year alone. During this time, OurPet’s has grown 3-5 times faster than the overall industry and has no plans of slowing down. The company gives investors the opportunity to participate in this expanding market while offering consumers the chance at buying multiple products through multiple brands.

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Late last month, Dominovas Energy Corp. made headlines when it secured a landmark commitment of $1.2 billion in project financing to fund the initial phase of production and deployment of its proprietary RUBICON™ solid oxide fuel cell technology. The company’s chairman and chief executive officer, Neal Allen, hailed the commitment as further validation of Dominovas Energy’s business model and “an undeniable endorsement of the technical prowess of the RUBICON™.” Earlier this week, Dominovas Energy successfully built on this progress when it announced a new commitment from Nevada-based GHS Capital for up to $7.5 million over the next 36 months.

“This commitment from GHS Capital serves as a catalyst for maintaining operational momentum established this year,” Eric Fresh, senior vice president of finance and investments with Dominovas Energy, stated in a news release. “Moreover, it solidifies the platform for continued business development and implementation of the company’s strategic vision for expansion and development of the RUBICON™ into the global frontier markets in 2016.”

Thus far in 2015, Dominovas Energy has implemented an aggressive growth strategy that should provide a solid platform for strong financial performance in the years to come. Since announcing its first power purchase agreement (PPA) for the City of David in the Democratic Republic of the Congo (DRC) earlier this year, the Company has committed to an ambitious goal of securing the project financing needed to support the deployment of over 200 megawatts of signed and guaranteed PPAs in the DRC while continuing to target other emerging markets throughout sub-Saharan Africa as part of President Obama’s Power Africa Initiative.

For prospective shareholders, emerging power generation markets in sub-Saharan Africa could represent an opportunity for Dominovas Energy to realize considerable financial growth moving forward, particularly as it continues to build an increasingly sizable foothold throughout the region. According to a report by market research firm McKinsey & Company, there are nearly 600 million people living in sub-Saharan Africa without access to electricity. In the DRC, just 20 percent of the population currently has average grid access. However, by 2040, the report suggests that more than 70 percent of the region will have access to reliable power generation, outlining the substantial opportunity for Dominovas Energy as it continues to pursue additional project financing.

“[W]e have put in place the building block that supports our innovation in engineering this next generation technology for the commercial production of clean and sustainable base load power via the proprietary RUBICON™,” added Allen. “Dominovas Energy actively demonstrates that the funding of power infrastructure projects in global and emerging markets is not only possible, but feasible.”

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Legacy Ventures International was recently highlighted in an article by a contributor at the investment research platform Seeking Alpha. The overview studied the company’s potential as a disruptive force in the multibillion dollar Canadian bottled water market.

Legacy is a Nevada-based multinational conglomerate focused on the acquisition of proven and high-potential businesses across a variety of sectors. With a list of corporate objectives circling around the concept of disruptive brands and ideas, Legacy seeks to deal in category game changers that provide maximized market impact and traction while promoting rapid and sustainable growth. A few months ago, the company implemented this strategy through the acquisition of Toronto-based RM Fresh Brands, and, along with it, the Canadian distribution rights to one of the most innovative and promising brands in the bottled water space – Boxed Water.

Boxed Water is a fresh approach to remedying the environmental nightmares associated with the ubiquitous plastic water bottle. To get a better idea of the problem, consider the current scale of the U.S. bottled water market. In 2013, wholesale revenues from bottled water approached $12.3 billion, led by major beverage brands such as Coca-Cola (NYSE: KO), Pepsico (NYSE: PEP) and Nestle (OTC: NSRGY). However, among the billions of bottles of water consumed each year, only 27 percent are recycled. As a result, more than two million tons of discarded water bottles have already been deposited into U.S. landfills.

Instead of plastic bottles, Boxed Water is packaged in a biodegradable box that’s reminiscent of a milk carton. The box is also key to the product’s brand identity. Carrying a simple message of ‘Boxed Water is Better’, this inconspicuous packaging effortlessly explains the concept of Boxed Water while attracting the attention of ecologically-aware consumers. The current challenge for Legacy is putting this message in front of its target audience. For that reason, the company is implementing a viral, event-driven marketing campaign throughout pivotal Canadian markets.

In recent months, Legacy has showcased Boxed Water at major events such as the Toronto Film Festival and Holt Renfrew’s Holiday Kick Off. These partnerships, in combination with Boxed Water’s straightforward packaging, are expected to play a key role in getting the word out about the product by getting it into the hands of celebrities and other influencers.

Boxed Water represents an opportunity for Legacy to disrupt the Canadian bottled water industry with an eco-friendly, easy-to-ship, deceptively simple solution. As the company continues to identify and target additional disruptive brands in both domestic and international markets, Boxed Water represents the first step in a long term strategic plan to maximize shareholder value for the foreseeable future.

To view the full Seeking Alpha article, visit http://seekingalpha.com/instablog/344872-jay-currie/4558426-legacy-ventures-disruption-in-a-box

For more information, visit www.legacyventuresinc.com

Let us hear your thoughts: Legacy Ventures International, Inc. Message Board

The true forefront in medicine today is a broad offensive where medical and research professionals are now pulling out all the stops in a never-ending war against broad-spectrum degenerative diseases like cancer or degenerative diseases of specific tissues, such as Parkinson’s and Alzheimer’s, which severely cripple a patient’s central nervous system (CNS). Unfortunately, there is very little in the way of truly therapeutic options for patients with degenerative CNS diseases.

In the case of Parkinson’s, dopamine-generating neurons in the midbrain (substantia nigra) progressively die off, resulting in a variety of motor control issues (dyskinesia) at first, with dementia, insomnia, and severe depression or emotional problems typically following in later stages. There is no currently known cure for Parkinson’s and the standard of care consists primarily of medications designed to manage and/or provide relief from the symptoms.

The main family of drugs used to offset Parkinson’s symptoms is Levodopa (L DOPA, which metabolizes into dopamine), but MAOIs (monoamine oxidase inhibitors) and dopamine agonists have seen a significant increase of use in recent years as a first choice, in order to prolong the start of L DOPA treatment. For you see, prolonged use of L DOPA typically results in dyskinesia that is equivalent to the long-term effects of Parkinson’s itself.

Because less than 10 percent of L-DOPA actually makes it through the blood-brain barrier, the vast majority of it is metabolized elsewhere in the body, resulting in numerous side effects like nausea and joint stiffness, in addition to the aforementioned Parkinson’s-like motor control problems. MAOIs, historically already in wide usage as a treatment for atypical depression, are pretty effective at delimiting the primary monoamine oxidase that degrades dopamine, MAO-B, and thus are able to somewhat offset the lack of dopamine that is being caused by neuronal loss.

As you can see, the only solutions for Parkinson’s patients which are currently available aren’t really solutions at all, and carry with them the looming inevitability of a lost battle against this degenerative disease. A truly disheartening reality for patients and their families. Long-term options for Parkinson’s patients and their families are severely limited as well and include invasive surgery, or palliative care designed merely to improve quality for end of life patients. Reasonable extrapolations from official Parkinson’s Disease Foundation data indicates that the number of people on earth currently suffering from the disease is likely close to, or over 10 million. Some 60,000 or more people in the U.S. alone are diagnosed with Parkinson’s each year, meaning the real number is likely much higher, after factoring in all the cases that go undiagnosed, and unreported.

Hence the undisputable potential value of the proprietary, scalable and ethical human parthenogenetic (asexual reproduction from unfertilized egg) stem cell (hpSC) technology currently being developed by International Stem Cell Corp. (OTCQB: ISCO). Because hpSCs are self-renewing multipotent cells, they represent an as-yet essentially untapped goldmine of therapeutic developments which could provide solutions for countless degenerative diseases, and do so across multiple tissue types. The company’s hpSC platform for chemically stimulating eggs to reproduce, which uses a series of different activation techniques in order to create sizeable batches of healthy adult cells that are HLA/immune-matched (human leukocyte antigen) either to the individual or to the general population, has led to an exciting novel therapeutic cellular product consisting of human parthenogenetic neural stem cells (hPNSCs).

Because hPNSCs have been shown to be able to actually differentiate into dopaminergic neurons, therapy using these injected cells represents a wholly-new approach to the problem of Parkinson’s, wherein the root cause of the disease is addressed directly. Moreover, transplanted hPNSCs have been shown to express powerful brain-protecting neurotrophic factors in pre-clinical animal model studies, meaning that not only does this product hold the potential to simply grow new dopamine-producing cells, it can also help shield the remaining healthy cells from degeneration and/or death. ISCO’s recent announcement that the company is now moving full steam ahead towards phase I/IIa human clinical trials in Australia, subsequent to a meeting with the Australian Therapeutics Goods Administration and signage of an LOI with the conducting facility, Royal Melbourne Hospital, is a major milestone for the company. A milestone that puts ISCO squarely in the pole position for developing the first true Parkinson’s therapy.

TGA approval for the phase I/IIa clinical trials is expected sometime this month, with enrollment commencing shortly after, and ISCO could have a real winner on its hands depending on whether the results jog with those generated by the preceding nine-month safety GLP study of 300 rodents, which showed zero tumor growth in any of the subjects receiving transplanted cells. ISCO seems to have overcome the two major stumbling blocks that have hindered other developers in this field: immune-related tissue rejection and tumor formation.

The chemically close-to-nature methodology whereby the company generates its hpSCs is likely a main reason its therapies have had such preclinical successes, and one need look no further than the results for the other candidates (such as those for metabolic liver and degenerative eye diseases) in ISCO’s therapeutic pipeline in order to get a good idea of where the Parkinson’s therapy is headed. A savvy observer will note that the probability of success for ISCO with its hPNSC phase I/IIa clinical trials is telegraphed readily by the demonstrated versatility of the platform in allowing for a robust pipeline of several promising indications. The hpSC platform looks solid and ISCO could have one or two disruptive commercial breakthroughs on its hands in the near future.

Unlike many preclinical biopharma developers, ISCO has a cash pipeline already in place to help fund the expensive work of drug trials, with two wholly-owned subsidiaries that benefit from the company’s hpSC platform: Lifeline Cell Technology and Lifeline Skin Care. Respectively engaged in the sale of human cell culture products/reagents, as well as cosmeceuticals based on a proprietary extract derived from hpSCs, these two profitable subsidiaries not only help feed the R&D machine that is ISCO, they represent promising long-term opportunities in and of themselves. Quarterly financial data out as of November 16 from ISCO shows that Lifeline Cell Technology sales were up handsomely in Q3 (ended September 30), climbing 22 percent compared to the same quarter last year, alongside a nine percent jump in the company’s total consolidated revenue over the same period. Having wound down its multiple preclinical studies during the first six months of 2015, ISCO has managed to slash its cash burn rate and the company is now eager to see the fruits of its labor emerge from human clinical trials of hPNSCs in Parkinson’s.

The ability to grow functional, immune-matched adult human stem cells without the need to fertilize an egg is as ground-breaking a revolution in medicine as it sounds. And ISCO is basically the tip of the spear here too, alongside a tiny handful of other companies, many of whom lack the crucial IP and pre-clinical success story to deliver on a platform solution that could eventually hit hard and fast across the gamut of degenerative and similar diseases.

To find out what the buzz is all about, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board